Fig. 7. In vivo antitumor activity of cRGD- mix Man-pRNC_{Thioether+DEA}@R848 in B16F10 tumor model.

a Schematic of treatment timeline in B16F10 tumor-bearing mice. b, c Average and individual tumor growth curves after different treatments (n = 5 mice per group). d Body weight changes within 20 days after inoculation (n = 5 mice per group). e, f Images and weight of tumor tissues collected on day 20 after different treatments (n =  5 mice per group). g Representative flow cytometry images and quantification of mature DCs in LNs (n = 3 mice per group). h Representative flow cytometric analysis and quantification of CD8⁺ and CD4⁺ T cells gating on CD3⁺ cells (n =  3 mice per group). i Representative flow cytometric analysis gating on CD47⁺ cells in tumors (n =  3 mice per group). j Representative flow cytometric analysis gating on PD-1⁺CD8⁺ cells in tumors (n = 3 mice per group). k Representative immunofluorescence images of Foxp3⁺ cells in tumors. Three times was repeated independently with similar results. Scale bar = 50 μm. Data are presented as mean ± SD. Statistical significance was calculated through one-way ANOVA for multiple comparisons using a Tukey post-hoc test.